Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi. https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl

Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA. https://t.co/LFfZAFgMWE https://t.co/n8X45pInYQ

Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth

EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4

Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA. https://t.co/spcdweO0pE https://t.co/0stEBPy6hc

Save the date! Join us on May 17th for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A. https://t.co/s7r09y5KNG https://t.co/0KYRPwGHsV

Bimekizumab's Favorable Safety Profile in Psoriasis A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis. https://t.co/84zS8VET6B https://t.co/aLvLmmTc93

#ClinicalPearl Autoantibodies in #Sjogren’s Syndrome include CCP and anticentromere - think of overlaps with #rheumatoid arthritis or lcSSc limited cutaneous systemic sclerosis #scleroderma #CCR22 #CCR2022 ⁦@RheumNow⁩ https://t.co/vrdbv640B5

Risk factors for readmission among 132,400 #SLE hospitalizatiions included young SLE, AIHA (OR 1.86) GN (OR 1.41) pericarditis (OR 1.4), CHF(OR 1.38), Medicare (OR 1.2), Medicaid (OR 1.26). Most Readm Dxs were Sepsis, CHF, pneumonia https://t.co/Nr9bCGDaw0 https://t.co/THO6KT6dWV

Systemic Sclerosis patients with Digital Ulcers used significantly more healthcare resources per year. Study of 104 SSc pts; w/ DU's had more severe disease, more tests, More HCP/Rheum visits, etc (p˂0.05) https://t.co/wWvrOye92c https://t.co/HsZfSrf5CV

We had a great TNR this week. Playback now available in case you missed it. This webinar presented excerpts from these lectures along with Q & A Psoriatic Arthritis Guidelines Drug Targeting in PsA PsA Registries and Real World Data https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg